Literature DB >> 11874562

Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2.

Francis M Ndungu1, Peter C Bull, Amanda Ross, Brett S Lowe, Ephantus Kabiru, Kevin Marsh.   

Abstract

There is longstanding evidence for a role of immunoglobulin (Ig)G in protection against malarial disease and infection. IgG1 and IgG3 have been shown to be particularly efficient at associating with monocytes in potentially protective mechanisms (i.e. antibody-dependent cellular inhibition, opsonization and phagocytosis). Conversely, there is some evidence that IgG2 (and possibly IgG4) antibodies may be antagonistic to this protection. The protective effect of IgG subclass antibody activity present before the beginning of a malaria transmission season (preseason antibody levels) against severe malaria has not been tested in longitudinal studies. We measured IgG class and subclass antibody levels specific to crude Plasmodium falciparum lysates by enzyme linked immunosorbent assay in a case-control study of 76 children on the coast of Kenya. The mean optical density values for both IgG class and subclass antibodies were not significantly different between the children who developed severe malaria and those who remained healthy during an observation period of two malaria transmission seasons. However, elevated levels of IgG1 in relation to levels of IgG2 and IgG4 antibodies were associated with protection from severe malaria (P = 0.02). Conversely, elevated levels of IgG2 in relation to IgG1 and IgG3 antibodies were associated with a higher risk of developing severe malaria (P = 0.006).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874562     DOI: 10.1046/j.0141-9838.2001.00440.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  35 in total

1.  Immunoglobulin G isotype responses to variant surface antigens of Plasmodium falciparum in healthy Gabonese adults and children during and after successive malaria attacks.

Authors:  Gerardo Cabrera; Clarisse Yone; Anne E Tebo; Jan van Aaken; Bertrand Lell; Peter G Kremsner; Adrian J F Luty
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

4.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

5.  Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens.

Authors:  Gregory S Noland; Paul Jansen; John M Vulule; Gregory S Park; Bartholomew N Ondigo; James W Kazura; Ann M Moormann; Chandy C John
Journal:  Acta Trop       Date:  2014-10-24       Impact factor: 3.112

6.  Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Authors:  Soe Soe; Michael Theisen; Christian Roussilhon; Khin-Saw Aye; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania.

Authors:  Method D Segeja; Bruno P Mmbando; Misago D Seth; John P Lusingu; Martha M Lemnge
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

8.  Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections.

Authors:  Cathrine Holm Olesen; Karima Brahimi; Brian Vandahl; Susana Lousada-Dietrich; Prajakta S Jogdand; Lasse S Vestergaard; Daniel Dodoo; Peter Højrup; Michael Christiansen; Severin Olesen Larsen; Subhash Singh; Michael Theisen
Journal:  Malar J       Date:  2010-10-26       Impact factor: 2.979

9.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

10.  Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort.

Authors:  N O Duah; D J C Miles; H C Whittle; D J Conway
Journal:  Parasite Immunol       Date:  2010-02       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.